Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AdvancePCS Expects Merger To Enhance Bid For Federal Employees Benefit

  • News

Executive Summary

Caremark/AdvancePCS' combined capacity will be a key component of its bid for the Federal Employees Health Benefit mail service contract, AdvancePCS CEO David Halbert said

You may also be interested in...



Caremark PCS Merger Wins Big Customer; Blues Move FEP Mail From Medco

Caremark will take over the mail service pharmacy program for the Blue Cross/Blue Shield Association Federal Employees Program effective Jan. 1

Caremark PCS Merger Wins Big Customer; Blues Move FEP Mail From Medco

Caremark will take over the mail service pharmacy program for the Blue Cross/Blue Shield Association Federal Employees Program effective Jan. 1

Medicare Discount Card Plans Will Be Profitable, AdvancePCS Says

AdvancePCS expects to profit from offering a Medicare-endorsed drug discount card, CEO David Halbert said

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS043240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By